Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) guidelines

Pain Physician

Volumn 11, Issue SPEC. ISS. 2, 2008, Pages

  Trescot, Andrea M ^a   Helm, Standiford ^b   Hansen, Hans ^c   Benyamin, Ramsin ^d,e   Glaser, Scott E ^f   Adlaka, Rajive ^g   Patel, Samir ^a   Manchikanti, Laxmaiah ^h,i   Datta, Sukdeb ^j   Sehgal, Nalini ^k   Colson, James ^l   Jordan, Art ^m   Lee, Marion ⁿ  

^a UNIVERSITY OF FLORIDA   (United States)

^b Pacific Coast Pain Management Center   (United States)

^c The Pain Relief Centers   (United States)

^d MILLENNIUM PAIN CENTER   (United States)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^f Pain Specialists of Greater Chicago   (United States)

^g Pain Control Associates   (United States)

^h PAIN MANAGEMENT CENTER OF PADUCAH   (United States)

ⁱ University of Louisville School of Medicine   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^l WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^m Coastal Interventional Pain Associates ^*  (United States)

ⁿ Pain Center   (United States)

more..

Author keywords

Adherence monitoring; Chronic pain; Controlled substances; Dependency; Diversion; Drug testing; Non cancer pain; Opioids; Persistent Pain; Prescription drug abuse; Prescription monitoring; Substance abuse

Indexed keywords

ALFENTANIL; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CODEINE; DEXTROPROPOXYPHENE; DIHYDROCODEINE; FENTANYL; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; ILLICIT DRUG; LEVORPHANOL; METHADONE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; MORPHINE SULFATE; NALOXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE AGONIST; OXYCODONE; OXYMORPHONE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PETHIDINE; PLACEBO; QUININE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANOREXIA; BLADDER DYSFUNCTION; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONFUSION; CONSENSUS DEVELOPMENT; CONSTIPATION; CONSULTATION; COST BENEFIT ANALYSIS; DELAYED STOMACH EMPTYING; DELIRIUM; DEPRESSION; DISEASE DURATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CONTROL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG INTOXICATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG MISUSE; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG UTILIZATION; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; FATIGUE; FUNCTIONAL STATUS; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE COST; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERALGESIA; IMMUNOPATHOLOGY; INFORMED CONSENT; LONG TERM CARE; LOW DRUG DOSE; MEDICAL DOCUMENTATION; MEMORY DISORDER; MONOTHERAPY; MUSCLE RIGIDITY; MUSCULOSKELETAL PAIN; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; OPIATE ADDICTION; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRURITUS; PSYCHOMOTOR DISORDER; RESPIRATION DEPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPINAL PAIN; STOMACH FUNCTION DISORDER; SUSTAINED DRUG RELEASE; SWEATING; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINALYSIS; VISCERAL PAIN; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; MONITORING, PHYSIOLOGIC; PAIN; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; SUBSTANCE-RELATED DISORDERS;

EID: 43649102347     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (350)